The delay in diagnosing ALS means treatment and supportive care is received later, which can have a significant impact on ...

Columnist Juliet Taylor's late husband, Jeff, always made Christmas special. To honor his memory, she carries on their ...

Help for family caregivers is urgently needed in the U.S., as the current situation is untenable, writes columnist.

Growing up in rural areas, having younger parents, and having less education may all be environmental risk factors for ALS, ...

Worrying about symptom progression a year after her diagnosis, columnist Dagmar Munn decided to develop her own resilience ...

The U.S. Food and Drug Administration (FDA) signaled that it may be willing to consider granting accelerated approval to ...

MN-166 (ibudilast) appears to benefit ALS patients over up to one year of use, an interim Phase 2b/3 trial analysis suggests.

The first ALS patient was dosed in a Phase 1 trial of Quralis' first-in-class therapy QRL-101, which is still enrolling at a ...

What is masitinib for ALS? Masitinib is an oral medication being developed by AB Science as a potential add-on treatment for slowing disease progression in people with amyotrophic lateral sclerosis ...

« MDA Engage Symposium: Irvine, CA Champions for Cures and Care Gala » ...

MaaT033, an experimental oral therapy for improving gut microbiome health, was shown to be safe and well tolerated in ALS ...